

DAFTAR PUSTAKA

1. Clark, P. E. *et al.* Bladder cancer. *Journal of the National Comprehensive Cancer Network: JNCCN* **11**, 446–475 (2013).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. *CA: a cancer journal for clinicians* **67**, 7–30, <https://doi.org/10.3322/caac.21387> (2017).
3. Babjuk, M. *et al.* EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *European urology* **71**, 447–461, <https://doi.org/10.1016/j.eururo.2016.05.041> (2017).
4. Alfred Witjes, J. *et al.* Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. *European urology* **71**, 462–475, <https://doi.org/10.1016/j.eururo.2016.06.020> (2017).
5. Chang, S. S. *et al.* Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. *The Journal of urology*, <https://doi.org/10.1016/j.juro.2016.06.049> (2016).
6. DeSantis, C. E. *et al.* Cancer treatment and survivorship statistics, 2014. *CA: a cancer journal for clinicians* **64**, 252–271, <https://doi.org/10.3322/caac.21235> (2014).
7. Jo, J. K. *et al.* The impact of preoperative anemia on oncologic outcome in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *International urology and nephrology* **48**, 489–494, <https://doi.org/10.1007/s11255-016-1219-x> (2016).
8. Moschini, M. *et al.* Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. *Anticancer research* **34**, 3225–3230 (2014).
9. Klinga, G. & Sherif, A. A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle- invasive urothelial urinary bladder cancer,

- with or without neoadjuvant chemotherapy. *SpringerPlus* **5**, 1167, <https://doi.org/10.1186/s40064-016-2865-2> (2016).
10. Eggers, H. *et al.* Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. *Medical oncology* **30**, 705, <https://doi.org/10.1007/s12032-013-0705-6> (2013).
 11. Lambert, J. W. *et al.* Using preoperative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer. *Urology* **81**, 587–592, <https://doi.org/10.1016/j.urology.2012.10.055> (2013).
 12. Temraz, S. *et al.* Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. *BMC urology* **14**, 76, <https://doi.org/10.1186/1471-2490-14-76> (2014).
 13. Ma, C. *et al.* Preoperative neutrophil-lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer. *OncoTargets and therapy* **9**, 4917–4922, <https://doi.org/10.2147/OTT.S107445> (2016).
 14. Zhang, G. M. *et al.* Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine* **36**, 8537–8543, <https://doi.org/10.1007/s13277-015-3613-x> (2015).
 15. Jabłonowski Z, Reszka E, Gromadzińska J, Wąsowicz W, Sosnowski M. Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. *Arch Med Sci* 2011; 7: 512-6.

16. Babjuk M, Burger M, Zigeuner R, Shariat S, Rhijn B.V, Comperat E et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. *Eur Urol*.2013 Oct;64(4):639-53.
17. Witjes J.A, Comperat E, Cowan N.C, De Santis M, Gakis G, Lebre T et al. Guidelines on muscle invasive bladder cancer. *European Association of Urology*. 2013: 7-10.
18. Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. *JAMA* 2011 Aug 17;306(7):737-45.
19. Pashos CL, Botteman MF, Laskin BL, et al. Bladder cancer: epidemiology, diagnosis, and management. *Cancer Pract* 2002 Nov-Dec;10(6):311-22.
20. Chrouser K, Leibovich B, Bergstralh E, et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. *J Urol* 2006 Jul;174(1):107-10.
21. Zelefsky MJ, Housman DM, Pei X, et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2012 ;83(3):953-9.
22. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer, Version 2.2016. National Comprehensive Cancer Network. June 23, 2016.
23. Chedgy EC, Black PC. Radical Cystectomy and the Multidisciplinary Management of Muscle-Invasive Bladder Cancer. *JAMA Oncol*. 2016.
24. Mitin T. Rethinking Radical Cystectomy as the Best Choice for Most Patients With Muscle-Invasive Bladder Cancer. *JAMA Oncol*. 2016.
25. Mercadante S, Gebbia V, Marrazzo A, Filosto S (2000) Anaemia in cancer: pathophysiology and treatment. *Cancer Treat Rev* 26(4):303–311

26. Birgegård G, Aapro MS, Bokemeyer C et al (2005) Cancer- related anemia: pathogenesis, prevalence and treatment. *Oncology* 68(Suppl 1):3–11
27. Amato AC, Pescatori M (1998) Effect of perioperative blood transfusions on recurrence of colorectal cancer—meta-analysis stratified on risk factors. *Dis Colon Rectum* 41(5):570–585
28. Pascual M, Bohle B, Alonso S et al (2013) Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism. *J Surg Res* 183(1):270–277
29. Bohlius J, Schmidlin K, Brillant C et al (2009) Recombinant human erythropoiesis stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. *Lancet* 373(9674):1532–1542
30. Hutterer GC, Krieger D, Mrcic E et al (2015) Preoperative leucocytosis, thrombocytosis and anemia as potential prognostic factors in non-metastatic renal cell carcinoma. *Anticancer Res* 35(6):3463–3469
31. Huang J, Feldman AS, Dong L et al (2015) Preoperative anemia as an independent prognostic indicator of papillary renal cell carcinoma. *Clin Genitourin Cancer* 13(5):e353–e360
32. Rink M, Sharifi N, Fritsche HM et al (2014) Impact of preoperative anemia on oncological outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol* 191(2):316–322
33. Gregg JR, Cookson MS, Phillips S, et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. *J Urol*. 2011;185:90-96.
34. Terry WJ, Bueschen AJ. Complications of radical cystectomy and correlation with nutritional assessment. *J Urol*. 1986;27:229-232.



UNIVERSITAS
GADJAH MADA

**FAKTOR PROGNOSTIK TERHADAP PEMULIHAN PASIEN KANKER KANDUNG KEMIH PASKA
OPERASI RADIKAL SISTEKTOMI**

RENDY TRIYAKA, dr. Ahmad Zulfan Hendri, Sp.U

Universitas Gadjah Mada, 2020 | Diunduh dari <http://etd.repository.ugm.ac.id/>

35. Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, Ninomiya K and Higashino K: Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. *Br J Cancer* 77: 907-912, 1998.
36. Borsig L: The role of platelet activation in tumor metastasis. *Expert Rev Anticancer Ther* 8(8): 1247-1255, 2008.